BMGL vs GDTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a positive revenue growth of 32.20% YoY and a gross margin of 26.29%, the company suffers from catastrophic profitability metrics including a -99.84% profit margin and -194.56% ROE, which undermine sustainable growth. Valuation multiples like Price/Book of 3.96 appear high given the lack of earnings and cash flow visibility, while the stock has lost over 80% of its value in the past year. The absence of Altman Z-Score and intrinsic value estimates further reflects data insufficiency and elevated distress risk.
GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.
Compare Another Pair
Related Comparisons
BMGL vs GDTC: Head-to-Head Comparison
This page compares Basel Medical Group Ltd (BMGL) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.